Wrinkles

... Anika Therapeutics Receives CE Mark for its REDEFYNE(TM) Cosmetic Tissue Augmentation Product Anika Therapeutics Receives CE Mark for its REDEFYNE(TM) Cosmetic Tissue Augmentation Product Designation Allows for Product to be Marketed in the European Union WOBURN, Mass., Feb.

16 /PRNewswire-FirstCall/ - Anika Therapeutics, Inc.

(Nasdaq: ANIK) today announced that it has received CE Mark approval to market its cosmetic tissue augmentation product, REDEFYNE(TM), in the European Union.

REDEFYNE is an injectable soft tissue filler for facial wrinkles, scar remediation and lip augmentation.

The product is based on Anika's chemically modified hyaluronic acid (HA) proprietary technology and incorporates lidocaine, a local anesthetic.

"Receiving approval to market our cosmetic tissue augmentation product in the European Union is a milestone achievement in our commercialization efforts," said Charles H.

Sherwood, Ph.D., Anika's president and chief executive officer.

"As previously announced, we filed a pre-market approval application (PMA) in September 2005, which is currently under review with the U.S.

Food and Drug Administration.

We are also actively seeking a partner to commercialize REDEFYNE worldwide." About Anika Therapeutics, Inc.

Headquartered in Woburn, Mass., Anika Therapeutics, Inc.

(http://www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, pro...

Read more...